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We report the case of successful treatment of a 31-year-old lady with cystic fibrosis and an en-bloc liver–pancreas transplant, who developed
cepacia syndrome on a background of chronic infection with the ET12 epidemic strain of Burkholderia cenocepacia. Combination therapy with
nebulised and intravenous meropenem and tobramycin led to clinical improvement with a return to baseline function and complete resolution of
the acute chest X-ray changes.
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A female was diagnosed with cystic fibrosis at age 13 months
by sweat test. She developed diabetes mellitus at 4 years of age,
thought to be type 1 due to recurrent episodes of ketoacidosis.
At 15 years of age she became infected with the ET12 epidemic
strain of Burkholderia cenocepacia. She had CF-related liver
cirrhosis and in 2000, at 25 years of age, she received an en-bloc
liver–pancreas transplant. Post-transplant she was no longer
diabetic, had normal liver and exocrine pancreatic function and
she remained clinically stable, requiring about one admission
per year for infective exacerbations of her chest disease.
Her brother, who also had cystic fibrosis, was infected with
the same strain of B. cenocepacia. He had received a successful
liver transplant in 1999, but had died of cepacia syndrome
2 years later.
At the time of admission in 2006 the patient was 31 years old
and had been feeling increasingly unwell for 5 days. She
described fever, increased sputum load, persistent coughing,
shortness of breath and chest discomfort consistent with an
acute infective exacerbation. She was pyrexial at 38.8 °C,⁎ Corresponding author. Tel.: +44 161 291 2154; fax: +44 161 291 2080.
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tory rate 26 breaths per minute) and auscultation of her lung
fields revealed bilateral coarse crepitations. Her initial blood
results demonstrated elevated white cell count (24.1×109/L)
and C-reactive protein (234 mg/L). The chest radiograph on
admission showed new bilateral pulmonary infiltrates. Sputum
culture prior to admission had grown Pseudomonas aeruginosa
and a pan-resistant B. cenocepacia. Her immunosuppressant
therapy at the time of her admission consisted of tacrolimus
(total daily dose 1.5 mg) and mycophenolate mofetil (500 mg
twice daily), and tacrolimus and mycophenolate mofetil trough
levels (4.8 mcg/L and 7.9 mcg/L respectively) were satisfactory.
Prior to admission she had a baseline forced expiratory volume
in 1 s (FEV1) of 1.35L (48% predicted) and a body mass index
of 18.4. Treatment including supplemental oxygen, intravenous
fluids, meropenem 2 gm three times daily, cotrimoxazole
960 mg twice daily and tobramycin 240 mg once daily was
commenced.
For the first 4 days she continued to spike fevers and developed
haemoptysis. A repeat chest X-ray showed bilateral progression
of pulmonary infiltrates. A CT-scan chest showed patchy nodular
consolidation throughout lung fields, small bilateral pleural
effusions as well as central bronchiectasis. Caspofungin and
ganciclovir were added to the treatment regimen pending results
of a PCR test for cytalomegalovirus and fungal cultures; thesed by Elsevier B.V. All rights reserved.
nFig. 1. Chest X-rays of the patient during (1a) and following recovery (1b) from
cepacia syndrome.
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were stopped. Over the next 3 days there was a general
improvement in her condition and her inflammatory marker
levels fell (white cell count 15.51×109/L and C-reactive protein
33 mg/L) on day 7.
On day 8 she began to deteriorate once more with recurrent
spikes of fever, increased dyspnoea and further progressive
changes on her chest X-ray consistent with progression of her
cepacia syndrome. Temocillin 2 g twice daily was added to her
antibiotic regimen. She continued to spike temperatures,
became oxygen dependent and was felt to be critically ill.
Cultures of sputum continued to yield B. cenocepacia but
P. aeruginosa was not isolated again during the admission and
no other organisms were detected despite several repeated blood
or sputum cultures.
Nebulised meropenem 250 mg (reconstituted in 5 ml in
sterile water and made to total volume of 10 ml using 0.9%
saline) twice daily was added to the treatment regimen on day
17 and nebulised high dose preservative-free tobramycin
(TOBI) 300 mg twice daily on day 25. Over the next 5 days
of admission her oxygen requirements decreased and inflam-
matory markers started to improve. She was able to maintain
peripheral saturations and mobilise without supplementary
oxygen and was clinically much improved. She was finally
discharged home after a total of 50 days of inpatient admission
and continued with nebulised meropenem once daily and nebu-
lised tobramycin twice daily.
At follow up in clinic 1week later her lung function was
stable and had returned to baseline and her functional status
continued to improve. The sputum samples after discharge
remained positive for B. cenocepacia and P. aeruginosa. The
nebulised meropenem was discontinued 3 months after
discharge and after 4 months a repeat chest X-ray had returned
to pre-admission baseline with complete resolution of the
radiological changes characteristic of cepacia syndrome. The
white cell count had improved to 7.3×109/L and C-reactive
protein level was 3 mg/L. Currently, now 16 months after the
episode of cepacia syndrome, she remains well.
2. Discussion
Since they were first identified as significant pathogens in the
1980s, B. cepacia complex species have been shown to be
associated with increased mortality in patients with cystic
fibrosis [1–4]. A well-recognised spectrum of infection exists,
ranging from chronic infection with more rapid loss of lung
function over time, to episodes of acute exacerbationwhere some
patients develop a necrotising pneumonia, sometimes, but
invariably, associated with bacteraemia during the terminal
phase, known as` ‘cepacia syndrome’. There are very few pub-
lished reports of successful management of the cepacia
syndrome. We have highlighted a case in which combined
intravenous and nebulised antibiotic therapy led to successful
treatment and return to baseline function in a patient with cystic
fibrosis and cepacia syndrome (Fig. 1). AlthoughB. cenocepacia
was isolated from sputum but not blood cultures, our extensive
experience of cepacia syndrome is that bacteraemia is not presentin many cases, and when detected is often only so in the
preterminal phase. The only pathogens isolated during the
admission were B. cenocepacia (consistently isolated from all
sputum cultures) and P. aeruginosa (only isolated in the initial
sputum culture but not when the patient began to further
deteriorate) and the clinical and radiological features are in
keeping with cepacia syndrome.
In the only previously published report of successful
treatment of cepacia syndrome, Kazachkov et al. described a
successful outcome of a case of cepacia syndrome following the
additional of high dose corticosteroids to the patient’s treatment
regimen [5]. In the present case, although corticosteriods were
not used, the patient was established on long-term immuno-
suppressive therapy following her liver–pancreas transplant.
This immunomodulation may have assisted in achieving a
successful respond to antibiotic treatment. However, the
cepacia syndrome developed when the patient was already
411A. Weidmann et al. / Journal of Cystic Fibrosis 7 (2008) 409–411taking immunosuppressant therapy and did not begin to resolve
until nebulised meropenem and tobramycin were included in the
treatment regimen. Furthermore, the patients’ brother who was
taking post-transplant immunosuppressant treatment suc-
cumbed to cepacia syndrome despite aggressive intravenous
antibiotic therapy.
The case that we describe demonstrates that even without a
fully understanding the pathogenesis of cepacia syndrome,
successful treatment and return to baseline function in patients
with cystic fibrosis may be possible. Combination nebulised
and intravenous antibiotic treatment may improve outcome with
cepacia syndrome. As our understanding of this interesting
group of pathogens evolves we hope that successful treatment
will become standard rather than exceptional.
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